Gunter von Minckwitz, Sebastian Harder, Sascha Hövelmann, Elke Jäger, Salah-Eddin al- Batran, Sibylle Loibl, Akin Atmaca, Christian Cimpoiasu, Antje Neumann, Aklil Abera, Alexander Knuth, Manfred Kaufmann, Dirk Jäger, Alexander B. Maurer, Winfried Wels
- Following publication of the data presented by von Minckwitz and colleagues it has been brought to our attention that some patients should be scored differently. Stable disease was seen in three of the eighteen patients instead of two of the eighteen patients: one patient with transitional cell carcinoma treated at 4 µg/kg scFv(FRP5)-ETA per day, and two breast cancer patients treated at 4 and 12.5 µg/kg scFv(FRP5)-ETA per day. Disease progression occured in 9 of the eighteen patients evaluated (see corrected Table 2 overleaf). This does not affect the conclusions of our study. In addition we would like to correct the following errors: patient IDs for patients U01 and U02 in the original Table 2 were interchanged. In addition, patient N03 had a grade 3 elevation of gamma-glutamyl transferase, and not grade 2 (see corrected Table 2 overleaf).
Deutsches Urheberrecht